Swiss-based startup EBAMed raises CHF 1.2 Million
Share this article
EBAMed Closes CHF 1.2 Million Seed Financing to Advance Non-Invasive Therapy for Heart Arrhythmias
EBAMed SA, a medical technology company enabling access to non-invasive treatments for heart arrhythmias, announces the successful completion of a CHF 1.2 million seed financing round on 21 August 2019. This first investment round was led by Fongit Seed Invest with the support of FONGIT, and includes several investors.
EBAMed develops medical devices to enhance protontherapy, a precise non-invasive treatment option for heart arrhythmia patients. The seed financing will be used to test EBAMed‘s first integrated ultrasound-based device to monitor heart motion and command the therapy machine. These pre-clinical tests are planned for 2020 in at least one protontherapy center in Europe or the United States.